KT-001
Version 1.0259ef79 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | KT-001 |
| Synonyms | KT001;KT 001 |
| SMILES | CCCCCCCCCC1(CCCCCC)OCC(CCCCN(CCCCO)CCCCC2COC(CCCCCC)(CCCCCCCCC)O2)O1 |
| Formula | C48H95O5N |
| M.Wt | 766.29 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
KT-001 is a novel ionizable cationic lipid developed by Vivas, Inc., disclosed in US 2026/0007612 A1 (published Jan 8, 2026).KT-001 demonstrates exceptional skeletal muscle targeting and low liver toxicity.Unlike traditional lipids that primarily accumulate in the liver, KT-001 avoids serum ApoE binding, preventing hepatic uptake. Upon intramuscular injection, it achieves a 29-fold reduction in liver off-target expression compared to standard lipids, while maintaining robust, long-lasting protein expression at the injection site.Its optimized pKa enables precise, pH-responsive endosomal escape for high transfection efficiency. KT-001 is an ideal carrier for localized mRNA vaccines and targeted therapeutics for muscle-related disorders.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →